Zimbabwe has rejected a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of Washington's demand for confidential data.
The decision became public after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson has since clarified that the United States was requesting biological samples for research and profit while refused to guarantee the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further negotiations to reach a agreement agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a similar health funding agreement following concerns were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and responsibility.
As per statements, 16 African countries have so far agreed to these new health pacts, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the end products would be available to our citizens if a future health crisis emerge."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting frameworks previously set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how subsequent collaboration might be designed in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body expressed it recognised the official position, but recommended that talks should continue since much of the nation's HIV programmes were funded by external financing.
"If specific concerns arise, such as those involving data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group added.
This impasse underscores the ongoing tensions between accepting crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.